Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06563869 | Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 |
| NCT06190782 | Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor | recruiting | Phase 3 | 354 | Fudan UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06354530 | A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 / Phase 3 | 266 | Army Medical Center of PLAOTHER_GOV | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy | recruiting | Phase 2 / Phase 3 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06194734 | A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer | recruiting | Phase 3 | 490 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05244798 | Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | not yet recruiting | Phase 3 | 420 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2024source: clinicaltrials